由于未能提交2024年第二季度10-Q表格,Celularity Inc.面临可能的退市;目标是在9月6日之前恢复合规,并可能延长到10月14日. Celularity Inc. faces potential delisting for failing to file Q2 2024 Form 10-Q; aims to regain compliance by Sept 6 with possible extension to Oct 14.
Nasdaq已通知再生医学公司Celuality Inc.公司,由于未能提交2024年Q2的10Q表格,没有遵守规定。 Celularity Inc., a regenerative medicine firm, has been notified by Nasdaq for non-compliance due to failure to file Form 10-Q for Q2 2024. 该公司的目标是在9月6日前提交一份计划,如获得批准,可延长至10月14日。 The company aims to regain compliance by submitting a plan by Sept 6, with potential extension to Oct 14 if approved. 尽管普通股和证券交易仍在继续, 但无法保证其会恢复合规性或满足纳斯达克的其他要求. Despite the trading of its common stock and warrants continuing, there's no guarantee of regaining compliance or meeting other Nasdaq requirements.